SE:SYNACT Stock Latest News
PremiumCompany AnnouncementsSynAct Pharma AB’s Q1 2025 Interim Report Highlights SynAct Pharma Secures Extended US Patent for Resomelagon Combination Therapy SynAct Pharma to Host Capital Markets Day Amidst Strategic Advancements